SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Actinium Pharmaceuticals, Inc. – ‘S-1’ on 1/31/14 – ‘EX-3.5’

On:  Friday, 1/31/14, at 5:29pm ET   ·   Accession #:  1213900-14-604   ·   File #:  333-193714

Previous ‘S-1’:  ‘S-1/A’ on 10/28/13   ·   Next & Latest:  ‘S-1/A’ on 2/12/14   ·   21 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 1/31/14  Actinium Pharmaceuticals, Inc.    S-1                   78:12M                                    Edgar Agents LLC/FA

Registration Statement (General Form)   —   Form S-1
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: S-1         Registration Statement (General Form)               HTML   1.68M 
 2: EX-3.5      Certificate of Amendment to Articles of             HTML     19K 
                Incorporation Filed January 7, 2014.**                           
 3: EX-4.8      Form of Common Stock Warrant, Dated December 27,    HTML     99K 
                2013 and January 10, 2014.**                                     
 4: EX-4.9      Form of Lock-Up Agreement, Dated December 27,       HTML     33K 
                2013.**                                                          
 5: EX-10.33    Actinium Pharmaceuticals, Inc. Amended and          HTML    186K 
                Restated 2013 Stock Plan.**                                      
 6: EX-10.34    Actinium Pharmaceuticals, Inc. Amended and          HTML    134K 
                Restated 2013 Equity Incentive Plan.**                           
 7: EX-10.35    Form of Unit Purchase Agreement, Dated December     HTML    166K 
                27, 2013 and January 10, 2014.**                                 
 8: EX-10.36    Form of Subscription Agreement, Dated December 27,  HTML    138K 
                2013 and January 10, 2014.**                                     
 9: EX-10.37    Form of Registration Rights Agreement, Dated        HTML    136K 
                December 27, 2013 and January 10, 2014.**                        
10: EX-10.38    Letter Agreement, Dated September 4, 2013, Between  HTML     20K 
                Actinium Pharmaceuticals, Inc. and Sloan-Kettering               
                Institute for Cancer Research.**                                 
11: EX-23.1     Accountants Consent                                 HTML     22K 
56: R1          Document and Entity Information                     HTML     33K 
45: R2          Consolidated Balance Sheets                         HTML     97K 
54: R3          Consolidated Balance Sheets (Parenthetical)         HTML     42K 
58: R4          Consolidated Statements of Operations               HTML     70K 
73: R5          Consolidated Statement of Changes in Stockholders'  HTML     93K 
                Equity                                                           
47: R6          Statements of Cash Flows                            HTML    124K 
53: R7          Description of Business and Summary of Significant  HTML     98K 
                Accounting Policies                                              
41: R8          Going Concern                                       HTML     30K 
32: R9          Related Party Transactions                          HTML     49K 
74: R10         Property and Equipment                              HTML     59K 
60: R11         Note Payable and Convertible Notes                  HTML     52K 
59: R12         Derivatives                                         HTML    148K 
64: R13         Income Taxes                                        HTML     68K 
65: R14         Commitments and Contingencies                       HTML    100K 
63: R15         Equity                                              HTML     95K 
66: R16         Stock Option Plan                                   HTML     66K 
55: R17         Warrants                                            HTML     71K 
57: R18         Employee Defined Contribution Plan                  HTML     25K 
62: R19         Subsequent Events                                   HTML     26K 
78: R20         Description of Business and Summary of Significant  HTML    145K 
                Accounting Policies (Policies)                                   
69: R21         Description of Business and Summary of Significant  HTML     47K 
                Accounting Policies (Tables)                                     
49: R22         Related Party Transactions (Tables)                 HTML     29K 
61: R23         Property and Equipment (Tables)                     HTML     55K 
51: R24         Note Payable and Convertible Notes (Tables)         HTML     39K 
26: R25         Derivatives (Tables)                                HTML    138K 
70: R26         Income Taxes (Tables)                               HTML     66K 
75: R27         Commitments and Contingencies (Tables)              HTML     51K 
36: R28         Stock Option Plan (Tables)                          HTML     55K 
35: R29         Equity (Tables)                                     HTML    100K 
39: R30         Warrants (Tables)                                   HTML     68K 
40: R31         Description of Business and Summary of Significant  HTML     30K 
                Accounting Policies (Details)                                    
42: R32         Description of Business and Summary of Significant  HTML     54K 
                Accounting Policies (Details Textual)                            
24: R33         Going concern (Details)                             HTML     38K 
67: R34         Related Party Transactions (Details)                HTML     25K 
48: R35         Related Party Transactions (Details Textual)        HTML    111K 
50: R36         Property and Equipment (Details)                    HTML     38K 
29: R37         Property and Equipment (Details Textual)            HTML     24K 
77: R38         Note Payable and Convertible Notes (Details)        HTML     40K 
18: R39         Note Payable and Convertible Notes (Details         HTML    106K 
                Textual)                                                         
43: R40         Derivatives (Details)                               HTML     69K 
72: R41         Derivatives (Details 1)                             HTML     54K 
28: R42         Derivatives (Details Textual)                       HTML     35K 
34: R43         Income Taxes (Details)                              HTML     39K 
38: R44         Income Taxes (Details 1)                            HTML     60K 
46: R45         Income Taxes (Details Textual)                      HTML     29K 
23: R46         Commitments and Contingencies (Details)             HTML     30K 
31: R47         Commitments and Contingencies (Details Textual)     HTML     34K 
20: R48         Commitments and Contingencies (Details Textual 1)   HTML    159K 
71: R49         Equity (Details)                                    HTML     55K 
27: R50         Equity (Details Textual)                            HTML    122K 
68: R51         Stock Option Plan (Details)                         HTML     44K 
30: R52         Stock Option Plan (Details Textual)                 HTML    103K 
44: R53         Warrants (Details)                                  HTML     36K 
19: R54         Warrants (Details 1)                                HTML     41K 
22: R55         Warrants (Details Textual)                          HTML     48K 
37: R56         Employee Defined Contribution Plan (Details)        HTML     29K 
25: R57         Subsequent Events (Details)                         HTML     29K 
76: XML         IDEA XML File -- Filing Summary                      XML    109K 
21: EXCEL       IDEA Workbook of Financial Reports                  XLSX    200K 
33: EXCEL       IDEA Workbook of Financial Reports (.xls)            XLS   1.55M 
12: EX-101.INS  XBRL Instance -- fil-20130930                        XML   2.27M 
14: EX-101.CAL  XBRL Calculations -- fil-20130930_cal                XML    133K 
15: EX-101.DEF  XBRL Definitions -- fil-20130930_def                 XML    739K 
16: EX-101.LAB  XBRL Labels -- fil-20130930_lab                      XML   1.46M 
17: EX-101.PRE  XBRL Presentations -- fil-20130930_pre               XML   1.02M 
13: EX-101.SCH  XBRL Schema -- fil-20130930                          XSD    261K 
52: ZIP         XBRL Zipped Folder -- 0001213900-14-000604-xbrl      Zip    179K 


‘EX-3.5’   —   Certificate of Amendment to Articles of Incorporation Filed January 7, 2014.**


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 C:   C:   C: 
Exhibit 3.5
 
 
 


21 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/26/24  Actinium Pharmaceuticals, Inc.    10-Q        3/31/24   49:10M                                    EdgarAgents LLC/FA
 3/29/24  Actinium Pharmaceuticals, Inc.    S-8         3/29/24    4:57K                                    EdgarAgents LLC/FA
 3/29/24  Actinium Pharmaceuticals, Inc.    10-K       12/31/23   65:17M                                    EdgarAgents LLC/FA
 2/02/24  Actinium Pharmaceuticals, Inc.    S-3/A                  3:589K                                   EdgarAgents LLC/FA
11/02/23  Actinium Pharmaceuticals, Inc.    10-Q        9/30/23   46:4.2M                                   EdgarAgents LLC/FA
 8/14/23  Actinium Pharmaceuticals, Inc.    10-Q        6/30/23   45:4M                                     EdgarAgents LLC/FA
 8/11/23  Actinium Pharmaceuticals, Inc.    S-3                    4:540K                                   EdgarAgents LLC/FA
 5/15/23  Actinium Pharmaceuticals, Inc.    10-Q        3/31/23   47:5.9M                                   EdgarAgents LLC/FA
 3/31/23  Actinium Pharmaceuticals, Inc.    10-K       12/31/22   60:8.1M                                   EdgarAgents LLC/FA
11/14/22  Actinium Pharmaceuticals, Inc.    10-Q        9/30/22   47:3.4M                                   EdgarAgents LLC/FA
 8/19/22  Actinium Pharmaceuticals, Inc.    S-8         8/19/22    5:185K                                   EdgarAgents LLC/FA
 8/12/22  Actinium Pharmaceuticals, Inc.    10-Q        6/30/22   48:3.7M                                   EdgarAgents LLC/FA
 5/13/22  Actinium Pharmaceuticals, Inc.    10-Q        3/31/22   44:2.7M                                   EdgarAgents LLC/FA
 3/25/22  Actinium Pharmaceuticals, Inc.    10-K       12/31/21   56:4.2M                                   EdgarAgents LLC/FA
11/12/21  Actinium Pharmaceuticals, Inc.    10-Q        9/30/21   42:3.1M                                   EdgarAgents LLC/FA
 7/30/21  Actinium Pharmaceuticals, Inc.    10-Q        6/30/21   44:3.2M                                   EdgarAgents LLC/FA
 5/14/21  Actinium Pharmaceuticals, Inc.    10-Q        3/31/21   43:2.3M                                   EdgarAgents LLC/FA
 3/31/21  Actinium Pharmaceuticals, Inc.    10-K       12/31/20   56:3.5M                                   EdgarAgents LLC/FA
10/23/20  Actinium Pharmaceuticals, Inc.    10-Q        9/30/20   41:2.6M                                   EdgarAgents LLC/FA
 8/14/20  Actinium Pharmaceuticals, Inc.    10-Q        6/30/20   44:2.8M                                   EdgarAgents LLC/FA
 8/07/20  Actinium Pharmaceuticals, Inc.    S-3                    4:702K                                   EdgarAgents LLC/FA
Top
Filing Submission 0001213900-14-000604   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Sun., Apr. 28, 7:12:28.2pm ET